| Literature DB >> 31584733 |
Maria-Eulàlia Juvé-Udina1,2,3, Jordi Adamuz2,3,4, Maria-Magdalena López-Jimenez2,3, Marta Tapia-Pérez4, Núria Fabrellas3,5, Cristina Matud-Calvo2,4, Maribel González-Samartino2,3,4.
Abstract
AIM: To assess the ability of the patient main problem to predict acuity in adults admitted to hospital wards and step-down units.Entities:
Keywords: acuity; clinical judgment; nursing intensity; patient classification systems; priority setting
Mesh:
Year: 2019 PMID: 31584733 PMCID: PMC7328732 DOI: 10.1111/jonm.12885
Source DB: PubMed Journal: J Nurs Manag ISSN: 0966-0429 Impact factor: 3.325
Baseline sample characteristics
| Characteristic | Study population | |
|---|---|---|
|
| ||
|
| % | |
| Age ≥75 years | 58,005 | 31.6 |
| Age (years)_median (IQR) | 67 | 53–78 |
| Male sex | 102,764 | 55.9 |
| Medical ward | 96,058 | 52.3 |
| Psychiatric ward | 608 | 0.3 |
| Step‐down unit | 13.582 | 7.4 |
| Unscheduled admission | 101,749 | 55.4 |
| Length of stay_median (IQR) | 4 | 2–8 |
| Continuity of care (discharged to another facility) | 7,330 | 4.0 |
| Reason for admission | ||
| Cardiocirculatory | 30,336 | 16.5 |
| Infectious | 27,208 | 14.8 |
| General surgery | 20,766 | 11.3 |
| Trauma and orthopaedics | 19,951 | 10.8 |
| Digestive, liver and pancreatic | 19,790 | 10.7 |
| Nervous system | 15,472 | 8.4 |
| Kidney and urinary tract | 13,959 | 7.6 |
| Respiratory | 10,971 | 6.0 |
| Reproductive | 8,257 | 4.5 |
| Head, neck and maxillofacial | 5,501 | 3.0 |
| Metabolic, nutritional and endocrinology | 3,064 | 1.7 |
| Haematopoiesis, blood and immunologic | 2,705 | 1.5 |
| Psychiatric, mental health and addictions | 1,192 | 0.6 |
| Skin and burns | 907 | 0.5 |
| Eyes | 857 | 0.5 |
| Other | 2,741 | 1.5 |
| Severity (APR‐GRD 3–4) | 43,557 | 23.7 |
| Risk of mortality (APR‐GRD 3–4) | 32,558 | 17.7 |
| Severity or risk of mortality (APR‐GRD 3–4) | 48,069 | 26.2 |
Abbreviations: IQR, interquartile range; APR‐DRG, all patient refined diagnosis‐related groups.
Main problems weights, variability and correspondence to acuity clusters
| Main problem |
| Weight |
| CI | PVC (%) | VAR | Acuity cluster | |
|---|---|---|---|---|---|---|---|---|
| Post‐ICU syndrome | 81 | 716 | 13.65 | 2.95 | 1.89 | Low | Superintensive | |
| Risk of multiorgan failure | 229 | 661 | 35.46 | 4.5 | 5.63 | Moderate | Intensive | |
| Risk of organ graft rejection | 134 | 625 | 20.94 | 3.45 | 3.42 | Low | Intensive | |
| Agony | 592 | 607 | 8.17 | 0.65 | 1.35 | Low | Intensive | |
| Risk of cardiac tamponade | 49 | 567 | 20.68 | 5.79 | 3.65 | Low | Preintensive | |
| Risk of disuse syndrome | 1,044 | 554 | 46.05 | 2.77 | 7.84 | Moderate | Preintensive | |
| Risk of cardiogenic shock | 330 | 549 | 4.87 | 0.51 | 0.88 | Low | Preintensive | |
| Risk of neurotoxicity recurrence/progression | 205 | 540 | 52.89 | 7.1 | 9.05 | Moderate | Preintensive | |
| Risk of ventricular arrhythmia | 51 | 538 | 6.08 | 1.65 | 1.13 | Low | Preintensive | |
| Risk of respiratory distress | 5,177 | 532 | 22.55 | 0.6 | 4.34 | Low | Preintensive | |
| Risk of hepatorenal syndrome | 602 | 524 | 27.7 | 2.18 | 5.17 | Moderate | Preintensive | |
| Risk of encephalopathy recurrence/progression | 511 | 520 | 12.3 | 1.05 | 2.36 | Low | Preintensive | |
| Risk of cardiorenal syndrome | 81 | 507 | 13.06 | 2.81 | 2.57 | Low | Preintensive | |
| Risk of acute pulmonary oedema | 5,326 | 505 | 24.74 | 0.65 | 4.77 | Low | Preintensive | |
| Risk of septic shock | 1,950 | 500 | 33.75 | 1.47 | 6.44 | Moderate | Intermediate | |
| Risk of thromboembolism | 190 | 498 | 13.5 | 1.9 | 2.69 | Low | Intermediate | |
| Risk of hypervolaemia | 501 | 486 | 14.1 | 1.22 | 2.96 | Low | Intermediate | |
| Risk of acidosis/alkalosis | 1,354 | 484 | 29.3 | 1.54 | 5.84 | Moderate | Intermediate | |
| Risk of acute deterioration | 964 | 482 | 1.57 | 0.09 | 0.32 | Low | Intermediate | |
| Risk of autonomic dysreflexia | 283 | 474 | 34.75 | 3.93 | 7.3 | Moderate | Intermediate | |
| Risk of thromboembolism recurrence/progression | 933 | 469 | 28.78 | 1.82 | 6.02 | Moderate | Intermediate | |
| Risk of chest tamponade | 600 | 463 | 7.88 | 0.62 | 1.7 | Low | Intermediate | |
| Risk of neurogenic shock | 48 | 455 | 36.16 | 9.73 | 7.94 | Moderate | Intermediate | |
| Risk of sepsis | 20,433 | 453 | 45.58 | 0.61 | 12.31 | High | Intermediate | |
| Risk of cachectic syndrome recurrence/progression | 112 | 450 | 8.83 | 1.61 | 1.96 | Low | Intermediate | |
| Risk of uraemic syndrome | 123 | 449 | 31.06 | 5.36 | 6.97 | Moderate | Intermediate | |
| Risk of hypovolemic shock | 610 | 447 | 19.04 | 1.41 | 4.24 | Low | Intermediate | |
| Risk of delirium recurrence/progression | 476 | 439 | 19.14 | 1.68 | 4.37 | Low | Intermediate | |
| Risk of brain vasospasm | 600 | 437 | 15.36 | 1.21 | 3.5 | Low | Intermediate | |
| Risk of hemodynamic instability | 589 | 436 | 1.77 | 0.14 | 0.41 | Low | Intermediate | |
| Risk of alkalosis | 215 | 424 | 6.13 | 0.81 | 1.44 | Low | Intermediate | |
| Risk of hypoxaemia recurrence/progression | 1,426 | 421 | 25.6 | 1.3 | 5.97 | Moderate | Intermediate | |
| Risk of brain ischaemia/haemorrhage recurrence/progression | 6,621 | 418 | 37.18 | 0.88 | 8.11 | Moderate | Intermediate | |
| Risk of hyper/hypovolaemia | 897 | 417 | 45.8 | 2.96 | 10.28 | High | Intermediate | |
| Risk of systemic inflammatory response syndrome | 4,392 | 415 | 32.86 | 0.95 | 7.82 | Moderate | Intermediate | |
| Risk of low cardiac output syndrome | 4,734 | 407 | 42.42 | 1.19 | 10.84 | High | Intermediate | |
| Risk of hypovolaemia recurrence/progression | 2,280 | 404 | 24.32 | 0.98 | 5.9 | Moderate | Intermediate | |
| Uncontrolled chronic pain | 472 | 404 | 1.6 | 0.14 | 0.4 | Low | Intermediate | |
| Risk of abdomen compartment syndrome | 351 | 394 | 25 | 2.57 | 6.3 | Moderate | Intensification | |
| Risk of suicidal intentionality recurrence/progression | 39 | 390 | 43.72 | 13.38 | 11.31 | High | Intensification | |
| Risk of liver failure | 1,376 | 389 | 39.79 | 2.07 | 10.35 | High | Intensification | |
| Risk of multiorgan toxicity | 542 | 382 | 16.66 | 1.31 | 4.35 | Low | Intensification | |
| Risk of ischaemia recurrence/progression | 1,101 | 380 | 15.85 | 0.92 | 4.15 | Low | Intensification | |
| Risk of hyperkalaemia | 40 | 380 | 5.05 | 1.57 | 1.33 | Low | Intensification | |
| Risk of effusion recurrence/progression | 565 | 373 | 21.94 | 1.75 | 5.9 | Moderate | Intensification | |
| Risk of myocardial ischaemia recurrence/progression | 7,205 | 371 | 2.56 | 0.05 | 0.69 | Low | Intensification | |
| Risk of hypovolaemia | 17,605 | 359 | 38.01 | 0.55 | 11.01 | High | Intensification | |
| Risk of increased intracranial pressure | 3,495 | 343 | 41.11 | 1.34 | 11.13 | High | Intensification | |
| Risk of biphasic anaphylaxis | 33 | 336 | 9.72 | 3.18 | 2.89 | Low | Intensification | |
| Risk of deliberated self‐harm | 194 | 335 | 1.14 | 0.15 | 0.34 | Low | Intensification | |
| Risk of peritonitis | 2,010 | 334 | 5.03 | 0.22 | 1.51 | Low | Intensification | |
| Risk of neurological deterioration | 2,882 | 331 | 55.75 | 1.99 | 14.41 | High | Intensification | |
| Risk of airway obstruction | 209 | 330 | 53.73 | 7.22 | 15.15 | High | Intensification | |
| Risk of ischaemia/haemorrhage | 3,114 | 324 | 30.15 | 1.04 | 8.88 | Moderate | Intensification | |
| Risk of neurotoxicity | 131 | 324 | 20.91 | 3.51 | 6.5 | Moderate | Intensification | |
| Risk of myocardial ischaemia | 1,297 | 323 | 8.33 | 0.44 | 2.58 | Low | Intensification | |
| Risk of compartment syndrome | 338 | 318 | 3.27 | 0.34 | 1.03 | Low | Intensification | |
| Risk of effusion | 199 | 318 | 2.34 | 0.33 | 0.73 | Low | Intensification | |
| Risk of hypoxaemia | 3,885 | 315 | 55.35 | 1.71 | 15.57 | High | Intensification | |
| Risk of complicated functional recovery | 51 | 311 | 11.07 | 2.95 | 3.55 | Low | Intensification | |
| Risk of hyper/hypoglycaemia | 52 | 310 | 20.41 | 5.12 | 6.55 | Moderate | Intensification | |
| Risk of haemorrhage recurrence/progression | 1,015 | 301 | 32.59 | 1.97 | 11.66 | High | Intensification | |
| Risk of delusion recurrence/progression | 302 | 300 | 16.98 | 1.88 | 5.64 | Moderate | Acute | |
| Risk of infection recurrence/progression | 5,155 | 299 | 39.35 | 1.05 | 13.29 | High | Acute | |
| Risk of nutritional deficit recurrence/progression | 59 | 298 | 2.28 | 0.58 | 0.76 | Low | Acute | |
| Risk of pancreatitis | 814 | 298 | 0.08 | 0.01 | 0.03 | Low | Acute | |
| Risk of hyperadrenergic syndrome | 83 | 296 | 40.59 | 8.68 | 13.32 | High | Acute | |
| Risk of sensory‐motor deficit | 840 | 292 | 18.95 | 1.26 | 6.34 | Moderate | Acute | |
| Risk of arrhythmia recurrence/progression | 2,442 | 287 | 34.75 | 1.36 | 12.67 | High | Acute | |
| Risk of anxiety‐depression syndrome | 515 | 283 | 7.91 | 0.67 | 2.76 | Low | Acute | |
| Risk of haemorrhage | 4,382 | 275 | 45.53 | 1.32 | 18.03 | High | Acute | |
| Risk of decreased intracranial pressure | 218 | 269 | 13.74 | 1.8 | 5.15 | Moderate | Acute | |
| Activity intolerance | 81 | 258 | 27.32 | 5.8 | 10.61 | High | Acute | |
| Risk of infection | 913 | 257 | 32.15 | 2.03 | 11.84 | High | Acute | |
| Risk of postoperative haemorrhage | 51,803 | 255 | 25.12 | 0.21 | 9.95 | Moderate | Acute | |
| Risk of hypocalcaemia | 1,113 | 243 | 5.55 | 0.32 | 2.28 | Low | Acute | |
| Risk of postoperative infection | 2,013 | 235 | 14.47 | 0.62 | 6.15 | Moderate | Acute | |
| TOTAL | 183,677 | |||||||
Abbreviations: SD, standard deviation; CI, 95% confidence interval; PVC, Pearson's variation coefficient; VAR, main problem mean weight variability.
Initial discriminatory capacity of the main problems
| Main problem |
|
% patients APR‐DRG 3–4 | % Likelihood | Predictive capacity |
Acuity cluster |
|---|---|---|---|---|---|
| Post‐ICU syndrome | 81 | 97.53 | 99.85 | Excellent | Superintensive |
| Risk of multiorgan failure | 229 | 90.39 | 99.36 | Excellent | Intensive |
| Risk of organ graft rejection | 134 | 85.07 | 98.94 | Excellent | Intensive |
| Agony | 592 | 83.95 | 98.85 | Excellent | Intensive |
| Risk of ventricular arrhythmia | 51 | 82.35 | 98.71 | Excellent | Preintensive |
| Risk of cardiac tamponade | 49 | 79.59 | 98.46 | Excellent | Preintensive |
| Risk of cardiogenic shock | 330 | 77.88 | 98.30 | Excellent | Preintensive |
| Risk of disuse syndrome | 1,044 | 73.18 | 97.82 | Excellent | Preintensive |
| Risk of respiratory distress | 5,177 | 72.51 | 97.75 | Excellent | Preintensive |
| Risk of cardiorenal syndrome | 81 | 70.37 | 97.50 | Excellent | Preintensive |
| Risk of neurotoxicity recurrence/progression | 205 | 69.76 | 97.43 | Excellent | Preintensive |
| Risk of hepatorenal syndrome | 602 | 69.27 | 97.37 | Excellent | Preintensive |
| Risk of encephalopathy recurrence/progression | 511 | 69.08 | 97.35 | Excellent | Preintensive |
| Risk of acidosis/alkalosis | 1,354 | 68.61 | 97.29 | Excellent | Intermediate |
| Risk of hypervolaemia | 501 | 67.07 | 97.10 | Excellent | Intermediate |
| Risk of acute pulmonary oedema | 5,326 | 61.12 | 96.27 | Excellent | Preintensive |
| Risk of autonomic dysreflexia | 283 | 60.42 | 96.17 | Excellent | Intermediate |
| Risk of thromboembolism | 190 | 60 | 96.10 | Excellent | Intermediate |
| Risk of septic shock | 1,950 | 59.49 | 96.02 | Excellent | Intermediate |
| Risk of haemodynamic instability | 589 | 56.37 | 95.50 | Excellent | Intermediate |
| Risk of acute deterioration | 964 | 55.08 | 95.28 | Excellent | Intermediate |
| Risk of neurogenic shock | 48 | 54.17 | 95.11 | Excellent | Intermediate |
| Risk of brain vasospasm | 600 | 51.83 | 94.65 | Excellent | Intermediate |
| Risk of chest tamponade | 600 | 51.17 | 94.51 | Excellent | Intermediate |
| Risk of thromboembolism recurrence/progression | 933 | 50.38 | 94.35 | Excellent | Intermediate |
| Risk of sepsis | 20,433 | 49.14 | 94.08 | Excellent | Intermediate |
| Risk of hypovolemic shock | 610 | 48.03 | 93.83 | Excellent | Intermediate |
| Risk of cachectic syndrome recurrence/progression | 112 | 47.32 | 93.66 | Excellent | Intermediate |
| Risk of hypoxaemia recurrence/progression | 1,426 | 46.42 | 93.44 | Excellent | Intermediate |
| Risk of alkalosis | 215 | 45.58 | 93.23 | Excellent | Intermediate |
| Risk of uraemic syndrome | 123 | 43.9 | 92.79 | Excellent | Intermediate |
| Risk of systemic inflammatory response syndrome | 4,392 | 40.78 | 91.88 | Excellent | Intermediate |
| Risk of delirium recurrence/progression | 476 | 39.5 | 91.47 | Excellent | Intermediate |
| Risk of hypovolaemia recurrence/progression | 2,280 | 38.46 | 91.13 | Excellent | Intermediate |
| Risk of hyper/hypovolaemia | 897 | 35.56 | 90.08 | Excellent | Intermediate |
| Uncontrolled chronic pain | 472 | 35.38 | 90 | Excellent | Intermediate |
| Risk of abdomen compartment syndrome | 351 | 35.04 | 89.87 | Very good | Intensification |
| Risk of effusion recurrence/progression | 565 | 33.45 | 89.21 | Very good | Intensification |
| Risk of brain ischaemia/haemorrhage recurrence/progression | 6,621 | 33.26 | 89.12 | Very good | Intermediate |
| Risk of low cardiac output syndrome | 4,734 | 32.81 | 88.93 | Very good | Intermediate |
| Risk of ischaemia recurrence/progression | 1,101 | 32.43 | 88.75 | Very good | Intensification |
| Risk of liver failure | 1,376 | 31.83 | 88.48 | Very good | Intensification |
| Risk of suicidal intentionality recurrence/progression | 39 | 30.77 | 87.97 | Very good | Intensification |
| Risk of hypovolaemia | 17,605 | 26.1 | 85.32 | Very good | Intensification |
| Risk of increased intracranial pressure | 3,495 | 25.18 | 84.69 | Very good | Intensification |
| Risk of airway obstruction | 209 | 24.88 | 84.50 | Very good | Intensification |
| Risk of myocardial ischaemia recurrence/progression | 7,205 | 24.09 | 83.92 | Very good | Intensification |
| Risk of deliberated self‐harm | 194 | 23.71 | 83.63 | Very good | Intensification |
| Risk of hyperkalaemia | 40 | 22.5 | 82.67 | Very good | Intensification |
| Risk of complicated functional recovery | 51 | 21.57 | 81.88 | Very good | Intensification |
| Risk of peritonitis | 2,010 | 21.44 | 81.79 | Very good | Intensification |
| Risk of biphasic anaphylaxis | 33 | 21.21 | 81.58 | Very good | Intensification |
| Risk of neurological deterioration | 2,882 | 20.16 | 80.58 | Very good | Intensification |
| Risk of neurotoxicity | 131 | 19.85 | 80.28 | Very good | Intensification |
| Risk of nutritional deficit recurrence/progression | 59 | 15.25 | 77.19 | Good | Acute |
| Risk of compartment syndrome | 338 | 16.86 | 76.96 | Good | Intensification |
| Risk of ischaemia/haemorrhage | 3,114 | 16.28 | 76.19 | Good | Intensification |
| Risk of hyper/hypoglycaemia | 52 | 15.38 | 74.94 | Good | Intensification |
| Risk of hypoxaemia | 3,885 | 15.08 | 74.49 | Good | Intensification |
| Risk of infection recurrence/progression | 5,155 | 13.39 | 74.39 | Good | Acute |
| Risk of myocardial ischaemia | 1,297 | 14.03 | 72.83 | Good | Intensification |
| Risk of multiorgan toxicity | 542 | 13.47 | 71.91 | Good | Intensification |
| Risk of effusion | 199 | 13.07 | 71.18 | Good | Intensification |
| Risk of haemorrhage recurrence/progression | 1,015 | 11.72 | 68.55 | Sufficient | Intensification |
| Risk of hyperadrenergic syndrome | 83 | 9.64 | 66.73 | Sufficient | Acute |
| Risk of pancreatitis | 814 | 9.21 | 65.61 | Sufficient | Acute |
| Risk of delusion recurrence/progression | 302 | 8.28 | 62.92 | Sufficient | Acute |
| Risk of haemorrhage | 4,382 | 5.82 | 49.20 | Not useful | Acute |
| Risk of anxiety‐depression syndrome | 515 | 5.44 | 47.37 | Not useful | Acute |
| Risk of infection | 913 | 5.15 | 45.95 | Not useful | Acute |
| Activity intolerance | 81 | 4.94 | 44.75 | Not useful | Acute |
| Risk of postoperative haemorrhage | 51,803 | 4.75 | 43.82 | Not useful | Acute |
| Risk of postoperative infection | 2,013 | 2.29 | 27.01 | Not useful | Acute |
| Risk of hypocalcaemia | 1,113 | 1.53 | 19.35 | Not useful | Acute |
| Risk of sensory‐motor deficit | 840 | 13.21 | 19.22 | Not useful | Acute |
| Risk of arrhythmia recurrence/progression | 2,442 | 10.52 | 15.54 | Not useful | Acute |
| Risk of decreased intracranial pressure | 218 | 9.17 | 13.64 | Not useful | Acute |
Abbreviations: APR‐DRG, all patient refined diagnosis‐related groups.
Final multivariate analysis and correspondence with the acuity patient classification system
| Main problem |
| OR | CI | p value | Acuity cluster | Weight | NHPPD | Range |
|---|---|---|---|---|---|---|---|---|
| Post‐ICU syndrome | 81 | 649.51 | 159.58–264.66 | <.001 | Superintensive | 716 | 14 | 14–23 |
| Risk of multiorgan failure | 229 | 154.72 | 99.58–240.39 | <.001 | Intensive | 661 | 12 | 10–13 |
| Risk of organ graft rejection | 134 | 93.73 | 58.22–150.90 | <.001 | Intensive | 625 | 10 | 10–13 |
| Agony | 592 | 86.03 | 68.92–107.38 | <.001 | Intensive | 607 | 10 | 10–13 |
| Risk of ventricular arrhythmia | 51 | 76.74 | 37.33–157.75 | <.001 | Preintensive | 538 | 8.25 | 7.5–10 |
| Risk of cardiac tamponade | 49 | 64.13 | 31.99–128.55 | <.001 | Preintensive | 567 | 9 | 7.5–10 |
| Risk of cardiogenic shock | 330 | 57.89 | 44.55–75.22 | <.001 | Preintensive | 549 | 8.25 | 7.5–10 |
| Risk of disuse syndrome | 1,044 | 44.87 | 38.98–51.64 | <.001 | Preintensive | 554 | 9 | 7.5–10 |
| Risk of respiratory distress | 5,177 | 43.38 | 40.50–46.47 | <.001 | Preintensive | 532 | 8.25 | 7.5–10 |
| Risk of cardiorenal syndrome | 81 | 39.05 | 24.21–62.99 | <.001 | Preintensive | 507 | 7.5 | 7.5–10 |
| Risk of neurotoxicity recurrence/progression | 205 | 37.93 | 28.10–51.18 | <.001 | Preintensive | 540 | 8.25 | 7.5–10 |
| Risk of hepatorenal syndrome | 602 | 37.06 | 31.08–44.20 | <.001 | Preintensive | 524 | 7.5 | 7.5–10 |
| Risk of encephalopathy recurrence/progression | 511 | 36.74 | 30.37–44.44 | <.001 | Preintensive | 520 | 7.5 | 7.5–10 |
| Risk of acidosis/alkalosis | 1,354 | 35.94 | 31.91–40.49 | <.001 | Intermediate | 484 | 7 | 5.5–7 |
| Risk of hypervolaemia | 501 | 33.49 | 27.72–40.45 | <.001 | Intermediate | 486 | 7 | 5.5–7 |
| Risk of acute pulmonary oedema | 5,326 | 25.84 | 24.25–27.54 | <.001 | Preintensive | 505 | 7.5 | 7.5–10 |
| Risk of autonomic dysreflexia | 283 | 25.11 | 19.74–31.93 | <.001 | Intermediate | 474 | 6.5 | 5.5–7 |
| Risk of thromboembolism | 190 | 24.67 | 18.42–33.03 | <.001 | Intermediate | 498 | 7 | 5.5–7 |
| Risk of septic shock | 1,950 | 24.15 | 21.94–26.57 | <.001 | Intermediate | 500 | 7 | 5.5–7 |
| Risk of hemodynamic instability | 589 | 21.24 | 18.00–25.08 | <.001 | Intermediate | 436 | 6 | 5.5–7 |
| Risk of acute deterioration | 964 | 20.17 | 17.69–22.98 | <.001 | Intermediate | 482 | 7 | 5.5–7 |
| Risk of neurogenic shock | 48 | 19.43 | 11.01–34.32 | <.001 | Intermediate | 455 | 6.5 | 5.5–7 |
| Risk of brain vasospasm | 600 | 17.7 | 15.03–20.83 | <.001 | Intermediate | 437 | 6 | 5.5–7 |
| Risk of chest tamponade | 600 | 17.23 | 14.64–20.28 | <.001 | Intermediate | 463 | 6.5 | 5.5–7 |
| Risk of thromboembolism recurrence/progression | 933 | 16.69 | 14.63–19.05 | <.001 | Intermediate | 469 | 6.5 | 5.5–7 |
| Risk of sepsis | 20,433 | 15.89 | 15.24–16.57 | <.001 | Intermediate | 453 | 6.5 | 5.5–7 |
| Risk of hypovolemic shock | 610 | 15.2 | 12.93–17.87 | <.001 | Intermediate | 447 | 6 | 5.5–7 |
| Risk of cachectic syndrome recurrence/progression | 112 | 14.77 | 10.18–21.43 | <.001 | Intermediate | 450 | 6 | 5.5–7 |
| Risk of hypoxaemia recurrence/progression | 1,426 | 14.25 | 12.78–15.89 | <.001 | Intermediate | 421 | 5.5 | 5.5–7 |
| Risk of alkalosis | 215 | 13.77 | 10.51–18.05 | <.001 | Intermediate | 424 | 5.5 | 5.5–7 |
| Risk of uraemic syndrome | 123 | 12.87 | 9.00–18.40 | <.001 | Intermediate | 449 | 6 | 5.5–7 |
| Risk of systemic inflammatory response syndrome | 4,392 | 11.32 | 10.58–12.12 | <.001 | Intermediate | 415 | 5.5 | 5.5–7 |
| Risk of delirium recurrence/progression | 476 | 10.73 | 8.91–12.93 | <.001 | Intermediate | 439 | 6 | 5.5–7 |
| Risk of hypovolaemia recurrence/progression | 2,280 | 10.28 | 9.39–11.25 | <.001 | Intermediate | 404 | 5.5 | 5.5–7 |
| Risk of hyper/hypovolaemia | 897 | 9.08 | 7.89–10.44 | <.001 | Intermediate | 417 | 5.5 | 5.5–7 |
| Uncontrolled chronic pain | 472 | 9 | 7.44–10.90 | <.001 | Intermediate | 404 | 5.5 | 5.5–7 |
| Risk of abdomen compartment syndrome | 351 | 8.87 | 7.11–11.07 | <.001 | Intensification | 394 | 5 | 3–5 |
| Risk of effusion recurrence/progression | 565 | 8.27 | 6.92–9.87 | <.001 | Intensification | 373 | 4.5 | 3–5 |
| Risk of brain ischaemia/haemorrhage recurrence/progression | 6,621 | 8.19 | 7.72–8.70 | <.001 | Intermediate | 418 | 5.5 | 5.5–7 |
| Risk of low cardiac output syndrome | 4,734 | 8.03 | 7.50–8.60 | <.001 | Intermediate | 407 | 5.5 | 5.5–7 |
| Risk of peripheral ischaemia recurrence/progression | 1,101 | 7.89 | 6.93–8.99 | <.001 | Intensification | 380 | 5 | 3.5–5 |
| Risk of liver failure | 1,376 | 7.68 | 6.83–8.64 | <.001 | Intensification | 389 | 5 | 3.5–5 |
| Risk of suicidal intentionality recurrence/progression | 39 | 7.31 | 3.70–14.44 | <.001 | Intensification | 390 | 5 | 3.5–5 |
| Risk of hypovolaemia | 17,605 | 5.81 | 5.55–6.08 | <.001 | Intensification | 359 | 4.5 | 3.5–5 |
| Risk of increased intracranial pressure | 3,495 | 5.53 | 5.09–6.01 | <.001 | Intensification | 343 | 4 | 3.5–5 |
| Risk of airway obstruction | 209 | 5.45 | 3.97–7.46 | <.001 | Intensification | 330 | 4 | 3.5–5 |
| Risk of myocardial ischaemia recurrence/progression | 7,205 | 5.22 | 4.90–5.56 | <.001 | Intensification | 371 | 4.5 | 3.5–5 |
| Risk of deliberated self‐harm | 194 | 5.11 | 3.67–7.13 | <.001 | Intensification | 335 | 4 | 3.5–5 |
| Risk of hyperkalaemia | 40 | 4.77 | 2.27–10.03 | <.001 | Intensification | 380 | 5 | 3.5–5 |
| Risk of complicated functional recovery | 51 | 4.52 | 2.32–8.82 | <.001 | Intensification | 335 | 4 | 3.5–5 |
| Risk of peritonitis | 2,010 | 4.49 | 4.02–5.02 | <.001 | Intensification | 334 | 4 | 3.5–5 |
| Risk of biphasic anaphylaxis | 33 | 4.43 | 1.92–10.21 | <.001 | Intensification | 336 | 4 | 3.5–5 |
| Risk of neurological deterioration | 2,882 | 4.15 | 3.77–4.57 | <.001 | Intensification | 331 | 4 | 3.5–5 |
| Risk of neurotoxicity | 131 | 4.07 | 2.65–6.26 | <.001 | Intensification | 324 | 3.5 | 3.5–5 |
| Risk of compartment syndrome | 338 | 3.34 | 2.51–4.44 | <.001 | Intensification | 318 | 3.5 | 3.5–5 |
| Risk of ischaemia/haemorrhage | 3,114 | 3.2 | 2.89–3.54 | <.001 | Intensification | 324 | 3.5 | 3.5–5 |
| Risk of hyper/hypoglycaemia | 52 | 2.99 | 1.41–6.35 | .004 | Intensification | 310 | 3.5 | 3.5–5 |
| Risk of hypoxaemia | 3,885 | 2.92 | 2.66–3.21 | <.001 | Intensification | 315 | 3.5 | 3.5–5 |
| Risk of myocardial ischaemia | 1,297 | 2.68 | 2.29–3.15 | <.001 | Intensification | 323 | 3.5 | 3.5–5 |
| Risk of multiorgan toxicity | 542 | 2.56 | 2.00–3.28 | <.001 | Intensification | 382 | 5 | 3.5–5 |
| Risk of effusion | 199 | 2.47 | 1.63–3.74 | <.001 | Intensification | 318 | 3.5 | 3.5–5 |
| Risk of haemorrhage recurrence/progression | 1,015 | 2.18 | 1.80–2.65 | <.001 | Intensification | 301 | 3.5 | 3.5–5 |
| Risk of delusion recurrence/progression | 302 | 1.69 | 1.12–2.55 | .012 | Intensification | 301 | 3.5 | 3.5–5 |
| Risk of infection recurrence/progression | 5,155 | 2.90 | 2.66–3.17 | <.001 | Intensification | 301 | 3.5 | 3.5–5 |
| Risk of nutritional deficit recurrence/progression | 59 | 3.38 | 1.66–6.88 | .001 | Intensification | 301 | 3.5 | 3.5–5 |
| Risk of pancreatitis | 814 | 1.90 | 1.50–2.42 | <.001 | Intensification | 301 | 3.5 | 3.5–5 |
The goodness of fit of the model was 1 and the area under the ROC curve was 0.814 (95% confidence interval 0.811–0.816).
Abbreviations: OR, odds ratio; CI, 95% confidence interval; NHPPD, nursing hours per patient day.
Final adjusted weight of the four MP initially located at the upper edge of the acute cluster that proved sufficient predictive ability.
Mean weight and intensity cluster adjusted according to univariate and initial multivariate analysis results.
Figure 1ROC curve of the model on the ability of the main problem to predict patient acuity [Colour figure can be viewed at https://www.wileyonlinelibrary.com]
X‐axis_specificity Y‐axis_sensitivity. Values: Goodness of fit of the model_1; Area under the ROC curve_0.814; Standard error_0.001; Asymptotic significance_0.000; 95% Confidence interval_0.811–0.816
Observed features and outcomes within each acuity cluster of the patient classification system
| Features and Outcomes | Acute | Intensification | Intermediate | Preintensive | Intensive | Superintensive | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
| |||||||
|
| % |
| % |
| % |
| % |
| % |
| % | |
| Clinical characteristics | ||||||||||||
| Age (years). median (IQR) | 62 | 48–73 | 66 | 52–77 | 71 | 58–81 | 76 | 65–84 | 65 | 54–77 | 64 | 56–74 |
| Age ≥75 years | 13,400 | 20.8 | 16,357 | 30.3 | 20,458 | 40.3 | 8,125 | 52.2 | 105 | 28.9 | 16 | 19.8 |
| Male sex | 32,147 | 49.9 | 32,885 | 60.8 | 29,428 | 57.9 | 7,752 | 58 | 215 | 59.2 | 59 | 72.8 |
| Severity or mortality risk (APR‐GRD 3–4) | 3,256 | 5.1 | 11,850 | 21.9 | 22,985 | 45.2 | 9,081 | 67.9 | 321 | 88.4 | 79 | 97.5 |
| ICU admission | 1,267 | 2 | 3,560 | 6.6 | 4,985 | 9.8 | 781 | 5.8 | 221 | 60.9 | 66 | 81.5 |
| LOS (days). median (IQR) | 2 | 1–4 | 5 | 3–8 | 7 | 4–11 | 7 | 5–12 | 15 | 8–30 | 62 | 33–90 |
| Continuity of care (another facility) | 1,539 | 2.4 | 1,720 | 3.2 | 3,300 | 6.5 | 726 | 5.4 | 26 | 7.2 | 17 | 21 |
| Outcomes | ||||||||||||
| Readmission (<31 days) | 654 | 1 | 2,497 | 4.6 | 4,286 | 8.4 | 1,491 | 11.1 | 32 | 8.8 | 1 | 1.2 |
| Transfer to ICU | 394 | 0.6 | 842 | 1.6 | 2,041 | 4 | 201 | 1.3 | 8 | 2.2 | 20 | 24.7 |
| Adverse event | 1,932 | 3 | 4,616 | 8.5 | 6,526 | 12.8 | 1,998 | 14.9 | 61 | 16.8 | 32 | 39.5 |
| Phlebitis | 1,527 | 2.4 | 3,321 | 6.1 | 3,913 | 7.7 | 1,018 | 7.6 | 32 | 8.8 | 11 | 13.6 |
| Pressure ulcer | 160 | 0.2 | 378 | 0.7 | 814 | 1.6 | 284 | 2.1 | 12 | 3.3 | 21 | 25.9 |
| Falls | 173 | 0.3 | 336 | 0.6 | 557 | 1.1 | 144 | 1.1 | 2 | 0.6 | 4 | 4.9 |
| Deceased | 150 | 0.2 | 811 | 1.5 | 1,695 | 3.3 | 734 | 5.5 | 21 | 5.8 | 8 | 9.9 |
Abbreviations: IQR, interquartile range; APR‐GRD, all patient refined diagnosis‐related group; ICU, intensive care unit; LOS, length of stay
Excluded those patients with Agony as the main problem for its relationship with mortality and other outcomes.
p value <0.001 (categorical variables were compared using the Fisher exact test and continuous variables using the Mann–Whitney test)
p value >0.001 and <0.05 (categorical variables were compared using the Fisher exact test and continuous variables using the Mann–Whitney test)